Want to learn more about the global impact of infectious diseases? Check out our detailed infographic filled with eye-opening statistics, such as:
While significant advances have been made in the control and prevention of infectious diseases, there is a clear need for therapeutic innovations, prompt and efficient diagnosis, and constant surveillance to meet their growing threat. Drug developers must conduct clinical trials prior to the emergence or spread of these diseases and deliver advanced therapies to control them.
Fortunately, governments around the world are playing an increasing role in supporting infectious disease drug development, and advanced technologies are making trials more efficient. Regulatory changes and clearer development guidelines coupled with investment incentives will help reinvigorate interest in infectious disease development.
Increasingly committed to antibiotic research and development, government agencies worldwide are exploring new incentives to foster interest and investment in antimicrobial drug development, encouraging pathogen-targeted development plans for targets such as carbapenem-resistant Enterobacteriaceae (CREs), which resist many antibiotics, and granting more approvals for smaller studies. For the first time, substantial funds are available from various federal agencies not only for basic science research, but also for drug development costs through Phase III.